AFC-HD AMS Life Science Co.,Ltd. Logo

AFC-HD AMS Life Science Co.,Ltd.

An OEM of health foods, supplements, and cosmetics, managing the full value chain from R&D to sales.

2927 | T

Overview

Corporate Details

ISIN(s):
JP3124700000
LEI:
Country:
Japan
Address:
静岡市駿河区豊田3丁目6番36号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

AFC-HD AMS Life Science Co., Ltd. operates as an original equipment manufacturer (OEM) specializing in health foods, dietary supplements, and cosmetics. Functioning as a holding company, it oversees a group of subsidiaries that manage the entire product value chain, from research and development to manufacturing and sales. The group's activities include direct mail order and wholesale distribution, the development and production of health-related media, and the manufacture of traditional Kampo medicines. The company leverages its integrated structure, including a dedicated R&D laboratory for product innovation and a GMP-certified manufacturing facility, to deliver a comprehensive range of quality products to its diverse customer base.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-07-15 08:30
Registration Form
有価証券届出書(組込方式)
Japanese 260.6 KB
2025-04-14 08:33
Regulatory News Service
確認書
Japanese 8.9 KB
2025-04-14 08:32
Interim Report
半期報告書-第45期(2024/09/01-2025/08/31)
Japanese 271.0 KB
2025-02-07 02:18
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 21.9 KB
2024-11-28 07:36
Post-Annual General Meeting Information
臨時報告書
Japanese 28.8 KB
2024-11-27 07:34
Governance Information
内部統制報告書-第44期(2023/09/01-2024/08/31)
Japanese 24.0 KB
2024-11-27 07:33
Registration Form
確認書
Japanese 8.9 KB
2024-11-27 07:32
Registration Form
有価証券報告書-第44期(2023/09/01-2024/08/31)
Japanese 1.2 MB
2024-11-21 03:12
Regulatory News Service
臨時報告書
Japanese 24.5 KB
2024-07-16 08:02
Report Publication Announcement
確認書
Japanese 8.9 KB
2024-07-16 08:02
Quarterly Report
四半期報告書-第44期第3四半期(2024/03/01-2024/05/31)
Japanese 211.7 KB
2024-04-15 08:08
Report Publication Announcement
確認書
Japanese 8.9 KB
2024-04-15 08:07
Quarterly Report
四半期報告書-第44期第2四半期(2023/12/01-2024/02/29)
Japanese 268.2 KB
2024-01-15 05:58
Report Publication Announcement
確認書
Japanese 8.9 KB
2024-01-15 05:57
Quarterly Report
四半期報告書-第44期第1四半期(2023/09/01-2023/11/30)
Japanese 214.8 KB

Automate Your Workflow. Get a real-time feed of all AFC-HD AMS Life Science Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for AFC-HD AMS Life Science Co.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for AFC-HD AMS Life Science Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Arctic Bioscience Logo
Develops pharma & nutra ingredients from marine lipids for autoimmune & wellness applications.
Norway ABS
ArcticZymes Technologies Logo
Develops novel enzymes from Arctic organisms for diagnostics, therapeutics, and biopharma.
Norway AZT
Arcturus Therapeutics Holdings Inc. Logo
Develops mRNA therapeutics and vaccines for rare respiratory, liver, and infectious diseases.
United States of America ARCT
Arcus Biosciences, Inc. Logo
A clinical-stage biopharma developing small molecule and antibody combination therapies for cancer.
United States of America RCUS
Arcutis Biotherapeutics, Inc. Logo
Develops and commercializes non-steroidal therapies for immune-mediated skin diseases.
United States of America ARQT
ARDELYX, INC. Logo
Biopharma developing first-in-class drugs for cardiorenal and GI diseases like IBS-C and CKD.
United States of America ARDX
ARECOR THERAPEUTICS PLC Logo
Biopharma firm enhancing drugs via reformulation for diabetes and pharmaceutical partners.
United Kingdom AREC
argenx SE Logo
Develops first-in-class antibody therapies for severe autoimmune diseases.
Netherlands 1AE
ARGENX SE Logo
Develops antibody-based therapies for severe autoimmune diseases, including its lead drug VYVGART.
United States of America ARGX
Armata Pharmaceuticals, Inc. Logo
Developing bacteriophage therapeutics for antibiotic-resistant infections.
United States of America ARMP

Talk to a Data Expert

Have a question? We'll get back to you promptly.